Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bimatoprost (lashes) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Prescription topical. Bimatoprost 0.03% is applied once daily as a thin line to the skin of the UPPER eyelid margin at the lash base (not to the lower lid, and avoid getting it in the eye), using a fresh applicator per eye. Continuous use is needed to maintain results. Use under a clinician, especially if you have glaucoma or take prostaglandin eye drops. There is no oral or systemic use. This library does not provide an ingestion protocol.
evening
Bimatoprost 0.03% solution (Latisse) with single-use applicators, under a clinician
Topical cosmetic only. HA serums are applied to clean, slightly damp skin once or twice daily and sealed with a moisturizer to hold water in (in very dry air, HA applied to dry skin can draw moisture outward). There is no oral, injectable, or systemic dose in this cosmetic context. This library does not provide an ingestion protocol.
any
Leave-on serum with high- and low-molecular-weight HA, sealed with a moisturizer
Throughout
8-16 weeks
2-6 months after stopping
Weeks to months
Throughout
1-8 weeks
4-8 weeks
Throughout
Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
Br J Dermatol (2015) · Rct
1-year double-masked RCT: composite primary endpoint (Global Eyelash Assessment + satisfaction) met for bimatoprost vs vehicle in idiopathic (40.2% vs 6.8%) and post-chemotherapy (37.5% vs 18.2%) hypotrichosis
Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
Aesthetic Plast Surg (2014) · Rct · n=209
Two double-masked vehicle-controlled RCTs (n=209: 173 idiopathic, 36 chemotherapy-induced) in Japanese subjects
The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.
Front Med (Lausanne) (2023) · Meta analysis
Meta-analysis of six placebo-controlled RCTs of topical prostaglandin analogs (incl. bimatoprost) for hair growth (lashes, brows, scalp)
Efficacy of cream-based novel formulations of hyaluronic acid of different molecular weights in anti-wrinkle treatment.
J Drugs Dermatol (2011) · Rct · n=76
Randomized split-face vehicle-controlled trial (n=76): 0.1% HA of five molecular weights (50-2000 kDa) twice daily to the periocular area for 60 days
Effectiveness of topical hyaluronic acid of different molecular weights in xerosis cutis treatment in elderly: a double-blind, randomized controlled trial.
Arch Dermatol Res (2024) · Rct · n=36
Double-blind RCT in 36 elderly subjects with dry skin: low-MW HA, high-MW HA, and vehicle lotions each on a separate leg site for 4 weeks
Efficacy of a New Topical Nano-hyaluronic Acid in Humans.
J Clin Aesthet Dermatol (2014) · Open label · n=33
Eight-week single-arm study of a low-molecular-weight nano-HA range (lotion, serum, cream) in 33 women
Bimatoprost (lashes) has a higher evidence score (8/10 vs 6/10) and wins in 2 of 3 categories.
No known interactions between Bimatoprost (lashes) and Hyaluronic Acid (topical) have been documented in our database. However, always consult a healthcare provider before combining supplements.